Literature DB >> 29759640

Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.

Shigeki Nakagawa1, Hirohisa Okabe2, Mayuko Ouchi2, Ryuma Tokunaga2, Naoki Umezaki2, Takaaki Higashi2, Takatoshi Kaida2, Kota Arima2, Yuki Kitano2, Hideyuki Kuroki2, Kosuke Mima2, Hidetoshi Nitta2, Katsunori Imai2, Daisuke Hashimoto2, Yo-Ichi Yamashita2, Akira Chikamoto2, Hideo Baba2.   

Abstract

BACKGROUND: Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and regulates tumor malignancy by gene silencing via histone methylation. In this study we investigate the role of EZH2 in angiogenesis of intrahepatic cholangiocarcinoma (ICC).
METHODS: The influence of EZH2 on tumor angiogenesis was examined by bioinformatics analysis of a public database. We also assessed the correlation between EZH2 and vasohibin 1 (VASH1) expression in 47 patients with ICC by immunohistochemical (IHC) staining and in vitro gene silencing assays. The prognostic significance of EZH2 and VASH1 expression by IHC was also examined in the ICC cohort.
RESULTS: Bioinformatics analysis showed that EZH2 was associated with several angiogenesis gene sets in the public database. EZH2 suppressed VASH1 expression in in vitro assays and IHC studies. EZH2-high/VASH1-low status was independently associated with poor disease-free survival (P = 0.019) and poor overall survival (P = 0.0055).
CONCLUSION: The current study demonstrated that high EZH2 expression was associated with activation of tumor angiogenesis, and activation of the EZH2-mediated angiogenesis pathway predicted the prognosis of patients with ICC.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Year:  2018        PMID: 29759640     DOI: 10.1016/j.hpb.2018.03.018

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  2 in total

Review 1.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

2.  Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation.

Authors:  Xuyang Lv; Jiangchuan Sun; Linfeng Hu; Ying Qian; Chunlei Fan; Nan Tian
Journal:  Aging (Albany NY)       Date:  2021-11-05       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.